mRNA-1040
Phase 1RNA therapy
ModernamRNA-1040 is one of 37 therapeutic programs targeting HIV. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
57 competitors in HIV
#DrugCompanyPhaseTrials
1Cabenuva
GSKApproved
Pifeltro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Tivicay
GSKPhase 3
Epivir
GGlaxo Dba Glaxosmithkline
Phase 3
Sunlenca
GileadPhase 3
Vemlidy
GileadPhase 3
Emtriva
GileadPhase 3
Biktarvy
GileadPhase 3
Priftin
SanofiPhase 2
Lamprene
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for mRNA-1040. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy
- Highest Phase
- Phase 1
- Company